®

MedChemExpress

| Cat. No.: | HY-P1050A | |
|----------------------|---|------|
| Molecular Formula: | C ₉₉ H ₁₈₂ F ₃ N ₃₇ O ₂₁ | |
| Molecular Weight: | 2283.78 | |
| Sequence: | Ac-Leu-Arg-Val-Arg-Leu-Ala-Ser-His-Leu-Arg-Lys-Leu-Arg-Lys-Arg-Leu-Leu-NH2 | alt) |
| Sequence Shortening: | Ac-LRVRLASHLRKLRKRLL-NH2 | |
| Target: | nAChR | |
| Pathway: | Membrane Transporter/Ion Channel; Neuronal Signaling | |
| Storage: | Sealed storage, away from moisture | |
| | Powder -80°C 2 years | |
| | -20°C 1 year | |
| | * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | |

SOLVENT & SOLUBILITY

| | 5 mg | 1 mg | Solvent Concentration | | |
|-----------|-----------|----------------------|--------------------------------------|------------------------------|---------|
| 4.3787 mL | 2.1894 mL | 0.4379 mL | 1 mM | Preparing Stock Solutions | |
| 0.8757 mL | 0.4379 mL | 0.0876 mL | 5 mM | | |
| 0.4379 mL | 0.2189 mL | 0.0438 mL | 10 mM | | |
| | | appropriate solvent. | ubility information to select the ap | Please refer to the solu | |
| | 0.2189 mL | | | | In Vivo |

| BIOLOGICAL ACTIV | ТТҮ |
|---------------------------|---|
| Description | COG 133 TFA is a fragment of Apolipoprotein E (APOE) peptide. COG 133 TFA competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 TFA is also a nAChR antagonist with an IC ₅₀ of 445 nM ^{[1][2]} . |
| IC ₅₀ & Target | IC50: 445 nM (nAChR) ^[2] |
| In Vivo | COG 133 (1 mg/kg; intratracheal administration; every other day; for 4 weeks) treatment impairs the resolution of pulmonary fibrosis in mice ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

COG 133 TFA

| Animal Model: | Male C57BL/6 mice (6-week-old) instilled with Bleomycin ^[3] |
|-----------------|--|
| Dosage: | 1 mg/kg |
| Administration: | Intratracheal administration; every other day; for 4 weeks |
| Result: | Did blunt the resolution of lung fibrosis. |

REFERENCES

[1]. Orleâncio Gomes R Azevedo, et al. Apolipoprotein E COG 133 mimetic peptide improves 5-fluorouracil-induced intestinal mucositis. BMC Gastroenterol. 2012 Jul 13;12:35.

[2]. Elaine A Gay, et al. Apolipoprotein E-derived peptides block alpha7 neuronal nicotinic acetylcholine receptors expressed in xenopus oocytes. J Pharmacol Exp Ther. 2006 Feb;316(2):835-42.

[3]. Huachun Cui, et al. Monocyte-derived alveolar macrophage apolipoprotein E participates in pulmonary fibrosis resolution. JCI Insight. 2020 Mar 12;5(5):e134539.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA